Piperlongumine
(Synonyms: 荜茇酰胺; Piplartine) 目录号 : GC10282
Piperlongumine是从Piper longum L.中提取的天然生物碱化合物,具有多种药理活性,包括抗肿瘤、脂质代谢调节、抗血小板聚集和镇痛活性等。
Cas No.:20069-09-4
Sample solution is provided at 25 µL, 10mM.
Piperlongumine is a natural alkaloid compound extracted from Piper longum L., which has multiple pharmacological activities, including anti-tumor, lipid metabolism regulation, anti-platelet aggregation and analgesic activities[1, 2]. Piperlongumine directly binds to and inhibits the antioxidant enzyme glutathione S-transferase Pi 1, leading to increased ROS levels in cancer cells and inducing cell apoptosis, while having no obvious toxicity to normal cells[3].
In vitro, treatment of leukemia U937 cells with Piperlongumine (0-20µM) for 48h inhibited cell proliferation in a time- and dose-dependent manner, induced cell apoptosis, increased the expression of intracellular anti-microtubule-associated protein 1A/1B-light chain 3 (LC3-I), and reduced the intracellular protein kinase B (Akt) level[4]. Piperlongumine (0-20µM) treatment of prostate cancer PC-3 cells, breast cancer MCF-7 cells and renal cancer 786-O cells induced cell autophagy, reduced the phosphorylation levels of intracellular Akt effectors, GSK-3β and TSC2, and led to increased intracellular ROS production[5]. Piperlongumine (0-5µM) treatment of thyroid cancer cell lines (IHH-4, WRO, 8505c and KMH-2 cells) for 24h and 48h inhibited the growth of all cells in a dose- and time-dependent manner, significantly reduced colony formation, and induced G2/M phase arrest and apoptosis[6].
In vivo, Piperlongumine (10mg/kg) was treated by intraperitoneal injection in BxPC-3 cell xenograft mice for 24 days, which significantly inhibited tumor growth, reduced microvascular density in pancreatic tumor tissues and induced cell apoptosis, and eliminated the increase in NF-κB activity in pancreatic tumor tissues induced by Gemcitabine[7]. Piperlongumine (50mg/kg/day) was treated orally in aged mice for 8 weeks, which significantly improved the novel object recognition and nesting behavior of aged mice, and increased the levels of calmodulin-dependent protein kinase IIα (CaMKIIα) and extracellular signal-regulated kinase 1/2 (ERK1/2) in the hippocampus[8].
References:
[1] Piska K, Gunia-Krzyżak A, Koczurkiewicz P, et al. Piperlongumine (piplartine) as a lead compound for anticancer agents–Synthesis and properties of analogues: A mini-review[J]. European journal of medicinal chemistry, 2018, 156: 13-20.
[2] Martha Perez Gutierrez R, Maria Neira Gonzalez A, Hoyo-Vadillo C. Alkaloids from piper: a review of its phytochemistry and pharmacology[J]. Mini Reviews in Medicinal Chemistry, 2013, 13(2): 163-193.
[3] Chen Y J, Kuo C C, Ting L L, et al. Piperlongumine inhibits cancer stem cell properties and regulates multiple malignant phenotypes in oral cancer[J]. Oncology letters, 2018, 15(2): 1789-1798.
[4] Wang H, Wang Y, Gao H, et al. Piperlongumine induces apoptosis and autophagy in leukemic cells through targeting the PI3K/Akt/mTOR and p38 signaling pathways[J]. Oncology Letters, 2018, 15(2): 1423-1428.
[5] Makhov P, Golovine K, Teper E, et al. Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death[J]. British journal of cancer, 2014, 110(4): 899-907.
[6] Kung F P, Lim Y P, Chao W Y, et al. Piperlongumine, a potent anticancer phytotherapeutic, induces cell cycle arrest and apoptosis in vitro and in vivo through the ROS/Akt pathway in human thyroid cancer cells[J]. Cancers, 2021, 13(17): 4266.
[7] Wang Y, Wu X, Zhou Y, et al. Piperlongumine suppresses growth and sensitizes pancreatic tumors to gemcitabine in a xenograft mouse model by modulating the NF-kappa B pathway[J]. Cancer Prevention Research, 2016, 9(3): 234-244.
[8] Go J, Park T S, Han G H, et al. Piperlongumine decreases cognitive impairment and improves hippocampal function in aged mice[J]. International Journal of Molecular Medicine, 2018, 42(4): 1875-1884.
Piperlongumine是从Piper longum L.中提取的天然生物碱化合物,具有多种药理活性,包括抗肿瘤、脂质代谢调节、抗血小板聚集和镇痛活性等[1, 2]。Piperlongumine直接结合并抑制抗氧化酶谷胱甘肽S-转移酶Pi 1,导致癌细胞内ROS水平升高,诱导细胞凋亡,而对正常细胞没有明显毒性[3]。
在体外,Piperlongumine(0-20µM)处理白血病U937细胞48h,以时间和剂量依赖性方式抑制了细胞增殖,诱导了细胞凋亡,增加了细胞内抗微管相关蛋白 1A/1B-light链3(LC3-I)的表达,降低了细胞内蛋白激酶B(Akt)水平[4]。Piperlongumine(0-20µM)处理前列腺癌PC-3细胞、乳腺癌MCF-7细胞和肾癌786-O细胞,诱导了细胞自噬,降低了细胞内Akt效应器、GSK-3β和TSC2的磷酸化水平,导致了细胞内ROS产生增加[5]。Piperlongumine(0-5µM)处理甲状腺癌细胞系(IHH-4、WRO、8505c和KMH-2细胞)24h和48h,以剂量和时间依赖性方式抑制了所有细胞生长,显著减少了集落形成,诱导G2/M 期停滞和细胞凋亡[6]。
在体内,Piperlongumine(10mg/kg)通过腹腔注射治疗BxPC-3细胞异种移植小鼠24天,显著抑制了肿瘤的生长,降低了胰腺肿瘤组织中的微血管密度并诱导细胞凋亡,消除了吉西他滨诱导的胰腺肿瘤组织中NF-κB活性的升高[7]。Piperlongumine(50mg/kg/day)通过口服治疗老年小鼠8周,显著改善了老年小鼠的新物体识别和筑巢行为,增加了海马体中钙调蛋白依赖性蛋白激酶IIα(CaMKIIα)和细胞外信号调节激酶1/2(ERK1/2)的水平[8]。
Cell experiment [1]: | |
Cell lines | U937 cells |
Preparation Method | U937 cells (2.5-5.0×104 cells/200µL of RPMI-1640 medium/well) were seeded in 96-well tissue culture plates and incubated with Piperlongumine (0-20µM) for 48h. MTT assay for measuring cell viability. |
Reaction Conditions | 0-20µM; 48h |
Applications | Piperlongumine could suppress the proliferation of U937 cells in a time- and dose-dependent manner. |
Animal experiment [2]: | |
Animal models | Nude BALB/c mice |
Preparation Method | Tumors were established by subcutaneous injection of 5×106 BxPC-3 cells into the flanks of mice. When tumors reached around 100mm3, the mice were randomly assigned to four groups: (i) control (DMSO was dissolved in 200μL PBS, once daily by i.p. injection); (ii) Piperlongumine (10mg/kg, once daily by i.p. injection); (iii) Gemcitabine (100mg/kg, twice weekly by i.p. injection); and (iv) Piperlongumine and Gemcitabine, following the same schedule of individual drugs. The mice were closely monitored for 24 days, then euthanized, and the tumors were removed. Each tumor was divided into two pieces: one fixed in 10% buffered formalin, and the other kept at −80°C for further analysis. |
Dosage form | 10mg/kg/day for 24 days; i.p. |
Applications | Piperlongumine alone can significantly inhibit tumor growth. Piperlongumine combined with Gemcitabine is more effective in reducing tumor burden. |
References: |
Cas No. | 20069-09-4 | SDF | |
别名 | 荜茇酰胺; Piplartine | ||
化学名 | 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one | ||
Canonical SMILES | COC1=CC(=CC(=C1OC)OC)C=CC(=O)N2CCC=CC2=O | ||
分子式 | C17H19NO5 | 分子量 | 317.34 |
溶解度 | ≥ 10.45mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 3.1512 mL | 15.756 mL | 31.5119 mL |
5 mM | 0.6302 mL | 3.1512 mL | 6.3024 mL |
10 mM | 0.3151 mL | 1.5756 mL | 3.1512 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet